• Hormone Insight

  • De: FWA
  • Podcast
  • Resumen

  • Discuss Diabetes and Endocrinology studies in a simplified manner. Expand your knowledge in Diabetes and Endocrinology.

    Copyright 2024 FWA
    Más Menos
Episodios
  • Exploring Semaglutide: Therapy for Obesity and Heart Failure
    Jan 4 2025

    Exploring Semaglutide: Dual Action Therapy for Obesity and Heart Failure

    In this episode of Hormone Insights, we delve into a 2024 study from the New England Journal of Medicine that examines the effects of semaglutide in obese patients with heart failure, preserved ejection fraction, and type 2 diabetes.


    For full paper, click here


    Visit HormoneInsight

    Más Menos
    1 m
  • Semaglutide vs Canagliflozin for Type 2 Diabetes
    Dec 19 2024

    In this episode of Hormone Insight, we delve into a major study published in The Lancet Diabetes and Endocrinology that compared the effects of semaglutide and canagliflozin as add-ons to metformin in diabetes treatment.


    For more: Semaglutide vs Canagliflozin for Type 2 Diabetes


    To read the original paper

    Más Menos
    1 m
  • Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients
    Nov 22 2024

    In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.


    For summary, click here.


    Packer M, Zile MR, Kramer CM, et al. (2024). “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.” New England Journal of Medicine. DOI: 10.1056/NEJMoa2410027


    Más Menos
    4 m
adbl_web_global_use_to_activate_webcro768_stickypopup

Lo que los oyentes dicen sobre Hormone Insight

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.